MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Anavex Life Sciences Corp

Gesloten

SectorGezondheidszorg

10.98 -0.72

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

10.72

Max

11.2

Belangrijke statistieken

By Trading Economics

Inkomsten

915K

-11M

Werknemers

42

EBITDA

106K

-12M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+157.69% upside

Dividenden

By Dow Jones

Volgende Winsten

5 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

201M

928M

Vorige openingsprijs

11.7

Vorige sluitingsprijs

10.98

Nieuwssentiment

By Acuity

50%

50%

154 / 376 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Anavex Life Sciences Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 jul 2025, 21:01 UTC

Winsten

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 jul 2025, 20:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

18 jul 2025, 20:50 UTC

Marktinformatie
Winsten

Auto & Transport Roundup: Market Talk

18 jul 2025, 20:50 UTC

Marktinformatie
Winsten

Basic Materials Roundup: Market Talk

18 jul 2025, 20:46 UTC

Winsten

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 jul 2025, 20:39 UTC

Acquisities, Fusies, Overnames

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 jul 2025, 20:36 UTC

Winsten

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 jul 2025, 20:16 UTC

Acquisities, Fusies, Overnames

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 jul 2025, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

18 jul 2025, 20:02 UTC

Marktinformatie

Gold Higher to Close Out Week -- Market Talk

18 jul 2025, 19:14 UTC

Marktinformatie

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 jul 2025, 19:06 UTC

Marktinformatie

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 jul 2025, 18:24 UTC

Winsten

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 jul 2025, 18:19 UTC

Winsten

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 jul 2025, 18:11 UTC

Acquisities, Fusies, Overnames

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 jul 2025, 18:11 UTC

Winsten

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 jul 2025, 17:35 UTC

Marktinformatie

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 jul 2025, 16:29 UTC

Marktinformatie

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 jul 2025, 16:28 UTC

Acquisities, Fusies, Overnames

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 jul 2025, 16:22 UTC

Winsten

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 jul 2025, 16:20 UTC

Marktinformatie
Winsten

Financial Services Roundup: Market Talk

18 jul 2025, 16:20 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

18 jul 2025, 16:20 UTC

Marktinformatie
Winsten

Auto & Transport Roundup: Market Talk

18 jul 2025, 16:20 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Energy & Utilities Roundup: Market Talk

18 jul 2025, 16:20 UTC

Marktinformatie
Winsten

Basic Materials Roundup: Market Talk

18 jul 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

18 jul 2025, 16:04 UTC

Winsten

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 jul 2025, 15:58 UTC

Marktinformatie

Global Equities Roundup: Market Talk

18 jul 2025, 15:58 UTC

Marktinformatie

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 jul 2025, 15:47 UTC

Marktinformatie
Winsten

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Peer Vergelijking

Prijswijziging

Anavex Life Sciences Corp Prognose

Koersdoel

By TipRanks

157.69% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 28.5 USD  157.69%

Hoogste 42 USD

Laagste 15 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Anavex Life Sciences Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Technische score

By Trading Central

8.275 / 9.312Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Neutral Evidence

Sentiment

By Acuity

154 / 376 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.